Expression and Significance of COX-2 and Ki-67 in Hepatolithiasis with Bile Duct Carcinoma

ABCD 1 Ping Wang
BC 2 Yu He
AC 3 Xiaodong Ma
DE 1 Beiwang Sun
FG 1 Binyuan Huang
DG 1 Canhua Zhu
CF 1 Yanmin Liu

Corresponding Author: Ping Wang, e-mail: migminggou15@163.com
Source of support: Research supported by the Medical Scientific Research Foundation of Guangdong Province, China (Grant No. A2013254)

Background: As an induced enzyme, COX-2 expression is elevated under stimuli from inflammatory mediator or growth factor product. Ki-67, a cell cycle-related proliferative antigen, reflects the tissue proliferative activity. This study analyzed the expressional profile of cyclooxygenase-2 (COX-2) and Ki-67 in hepatolithiasis and bile duct carcinoma tissues, in an attempt to provide evidence for diagnosis and prognosis prediction of disease.

Material/Methods: A cohort of tissue samples from hepatolithiasis with bile duct carcinoma (N=47) patients were analyzed using immunohistochemical (IHC) staining method for the expression of COX-2 and Ki-67, in parallel with hepatolithiasis (N=44) and normal bile duct tissues (N=30). The relationship between expression pattern of COX-2 and Ki-67 and pathological conditions was also analyzed, in addition to the correlation with positive expression in hepatolithiasis samples.

Results: The positive expression rate of COX-2 and Ki-67 in bile duct carcinoma was 76.6% and 80.9%, respectively, and was significantly higher than those in the hepatolithiasis group, which was also higher than the control group. Expression of both COX-2 and Ki-67 is closely related to TNM staging, lymph node metastasis, and different stages. They were also correlated with the mortality rate of patients.

Conclusions: Both COX-2 and Ki-67 are abundantly expressed in hepatolithiasis and bile duct carcinoma tissues and may play an important role in the disease occurrence, progression, and metastasis.

MeSH Keywords: Adenoma, Bile Duct • Bile Duct Neoplasms • Cyclooxygenase 2 Inhibitors

Full-text PDF: http://www.medscimonit.com/abstract/index/idArt/894330
Background

Although hepatolithiasis is a common disease, the combination of hepatolithiasis and bile duct carcinoma only accounts for 1~3% of total cases [1]. Hepatolithiasis patients typically manifest with jaundice, fever, and upper abdominal pains. But once being complicated with bile duct cancer, patients often present typical symptoms similar to those of hepatolithiasis with cholangitis. Imaging examination, on the other hand, may not clearly visualize the tumor due to the coverage by the lithiasis. Serum tumor markers such as CA199 have inherent high sensitivity but low specificity. Due to such diagnostic difficulty and its insidious onset, hepatolithiasis with bile duct carcinoma patients often receive confirmed diagnosis only at a late stage, thus severely compromising patient prognosis. It is well known that angiogenesis is closely related with the invasion and metastasis of malignant tumors [2]. Cyclooxygenase (COX) is a critical enzyme converting arachidonic acid into prostaglandin. There are 2 isozymes of COX: COX-1 potentiates the formation of new vessels in tumors and COX-2 has high expression under the stimuli of inflammatory mediator or growth factors [3].Ki-67, on the other hand, is a proliferative antigen closely related with cell cycle regulation, as supported by its pleiotropic functions in cytokinetics and oncogenesis [4]. Studies have shown that the co-assay of COX-2 and Ki-67 expression had significantly higher sensitivity or specificity in breast cancer invasive ductal carcinoma when compared to either single test [5]. The present study therefore investigated the co-expression of COX-2 and Ki-67 in hepatolithiasis with bile duct carcinoma patients, in an attempt to find the significance of gene expression in disease occurrence and progression.

Material and Methods

Patient information

A total of 44 patients diagnosed with hepatolithiasis with bile duct carcinoma in our hospital between April 2012 and January 2014 were recruited in this study, along with 47 hepatolithiasis patients. Inclusion criteria: (1) had not received surgical resection or radio-/chemo-/hormonal treatment before tissue collection; (2) with full information of clinical/TNM staging; (3) with confirmed diagnosis of hepatolithiasis with bile duct carcinoma by post-operative pathological examination. Exclusion criteria: (1) complicated with other malignant tumors; (2) incomplete medical history; (3) accompanied with acute or chronic infection. There were 27 males and 20 females in the cancer group, ages 37~73 years old (average age=62.5±3.9 years). A further TNM staging following the American Joint Committee on Cancer (AJCC) standard [4] identified 6 stage I patients, 11 stage II patients, 12 stage III patients, and 18 stage V patients. Lymph node metastasis were discovered in 13 patients. A further differentiation score based on Gleason system [6] showed 7 low, 21 moderate, and 19 highly differentiated tumors. The invasive condition of tumors was: 11 cases of deep muscular layer invasion; 26 cases of shallow muscular layer invasion, and 10 cases without any invasion. Among 47 hepatolithiasis patients, 26 were males and 21 were females, ages 36~77 years old (average age=61.8±4.5 years). Thirty samples of normal bile duct tissues from hemangioma resection were recruited in the control group. There were 17 males and 13 females, ages 35~79 years old (average age=62.1±4.5 years).

The study protocol was approved by the Research Ethics Committee of our hospital, and all patients gave their informed consent before study commencement.

Histological staining and scoring

All tissue samples were frozen and sectioned for further hematoxylin-eosin staining and immunohistochemical (IHC) staining following standard protocols as stipulated in the IHC kit (GIBCO, US). Mouse anti-human COX-2 and rabbit anti-human Ki-67 antibody were purchased from Baijing Biotech (China). Parallel negative controls were performed using PBS to replace the primary antibody. Five high-magnification fields were randomly selected from each slide. The staining score was calculated as the product of: (1) percentage of positive cells and (2) staining intensity. In brief, the positive cell% was deduced as 0, 1, 2, and 3 scores when positive cells accounts for less than 5%, between 5% and 25%, between 26% and 50%, and more than 50% of total cells, respectively. The staining intensity score was 0 for no color, 1 for moderate staining, and 2 for intensive staining. The total scores (cell percentage score X staining intensity score) thus range between 0 and 6. Negative (–), weak positive (+), moderate positive (++), and strong positive (+++) were defined for scores of 0~1, 2~3, 3~4, and 5~6, respectively.

Statistical analysis

The SPSS 20.0 software package was used to process all collected data, among which analysis of variance (ANOVA) was used for multiple group comparisons. Further between-group analysis was performed by Bonferroni post-hoc test. Enumeration data, on the other hand, was presented as percentage (%) and was tested by chi-square method. Cox regression method was used to analyze the factors of prognosis. A statistical significance was defined when p<0.05.
Results

Staining of COX-2 and Ki-67

As shown in Figure 1, COX-2 mainly existed in the cytoplasm in tumor cells, while Ki-67 protein was concentrated in the nucleus of tumor cells.

Positive rate of COX-2 and Ki-67

Further analysis showed that the positive rate of COX-2 and Ki-67 in bile duct carcinoma group was 76.60% and 80.85%, respectively, with significant elevation compared to those in control or hepatolithiasis group (p<0.05). Those rates in the hepatolithiasis tissues were also significantly higher than control group (p<0.05), as shown in Table 1 and Figure 2.

Table 1. Positive rate of COX-2 and Ki-67 proteins.

| Group               | N  | COX-2 |     |     |     | Positive rate | N  | COX-2 |     |     |     | Positive rate |
|---------------------|----|-------|-----|-----|-----|---------------|----|-------|-----|-----|-----|---------------|
|                     |    |       |   - |   + | ++  | [n (%)]       |    |       |   - |   + | ++  | [n (%)]       |
| Control             | 30 | 29    | 0  |    | 1   | 0 1 (3.33)    | 30 | 0     |    | 0  | 0   | 0             |
| Hepatolithiasis     | 47 | 33    | 1  | 0  | 13  | 14 (29.79)    | 35 | 12    |    | 0  | 0   | 12 (25.53)    |
| Bile duct cancer    | 47 | 11    | 3  | 12 | 21  | 36 (76.60)    | 9  | 10    | 13 | 25 | 38  | 38 (80.85)    |

COX-2 and Ki-67 expression and clinical features

As shown in Tables 2 and 3, positive expression rate of both COX-2 and Ki-67 were significantly correlated with various clinical parameters including TNM staging, lymph node metastasis and differentiation grade (p<0.05). Other general parameters such as patient age, sex, pathological type and size of tumors were not related to protein expression (p>0.05).

Regression analysis of survival rates

Within 12-month follow-up, 43 patients survived within a total of 47 bile duct cancer patients, making the 1-year survival rate 91.59%. We further performed a COX regression survival model, considering patient age, sex, disease period, lymph node metastasis, TNM staging, differentiation grade, tumor
size, tumor type, and expression of COX-2 and Ki-67. Results (Table 4) identified 4 factors significantly related to the survival rate: Ki-67 positive rate, COX-2 positive rate, tumor differentiation grade, and TNM staging.

Discussion

The combined treatment plan involving surgical resection and chemo-/radio-therapy has obtained satisfactory results in bile duct carcinoma, especially for those early-stage tumors. Postoperative follow-ups, however, showed that about 17–51% of patients develop distal metastasis, in addition to the 6–21% rate of local recurrence within 3–5 years after surgery [7]. Such recurrent tumors are more difficult to treat and usually lead to death within 1 year. Past studies have identified the history of hepatolithiasis as a risk factor of bile duct carcinoma, mainly due to the persistent mechanical stimuli on the bile duct wall [8]. Currently, there are many biomarkers for evaluating the prognosis of bile duct carcinoma patients, such as growth factor, vesicular endothelial growth factor (VEGF), and transforming growth factor (TGF)-β1 [9].

As shown in this study (Figure 1), Ki-67 mainly locates in the nucleus, consistent with its major functions in mitosis. Previous studies have found an important role of Ki-67 in cell proliferation, as it is both a structural protein and scaffold of chromosomes [10]. Recent studies further identified the relationship between Ki-67 and cell cycle. Because an important feature of tumor cells is the loss of cell cycle control and hyper-proliferation, Ki-67 has been widely used as an index reflecting the proliferative activity and recurrence possibility of malignant tumors, including urinary cancer, breast cancer, gastrointestinal cancer, and lung cancer [11]. For example, Ki-67

![Figure 2. COX-2 and Ki-67 positive rates. Averaged positive rates (in%) were plotted across control, hepatolithiasis, and bile duct carcinoma groups.](image)

| Table 2. COX-2 expression and clinical indexes. |
|-----------------------------------------------|
| Clinical parameter | N | Positive cases | Percentage | $\chi^2$ value | P value |
| Age (yrs) | | | | | |
| <60 | 31 | 22 | 70.97 | 1.609 | 0.205 |
| ≥60 | 16 | 14 | 87.50 | | |
| Sex | | | | | |
| Male | 27 | 21 | 77.78 | 0.049 | 0.824 |
| Female | 20 | 15 | 75.00 | | |
| Disease history (yr) | | | | | |
| <3 | 15 | 10 | 66.67 | 1.212 | 0.271 |
| ≥3 | 32 | 26 | 81.25 | | |
| Tumor size (cm) | | | | | |
| <2 | 19 | 13 | 68.42 | 1.189 | 0.275 |
| ≥2 | 28 | 23 | 82.14 | | |
| Type | | | | | |
| Squamous | 4 | 3 | 75.00 | 0.006 | 0.937 |
| Adenoma | 43 | 33 | 76.74 | | |
| Differentiation | | | | | |
| Low | 10 | 10 | 100.00 | | |
| Moderate | 21 | 17 | 76.19 | 5.987 | 0.017 |
| High | 16 | 9 | 68.75 | | |
| Lymph node metastasis | | | | | |
| Yes | 24 | 22 | 91.67 | 6.214 | 0.013 |
| No | 23 | 14 | 60.87 | | |
| TNM staging | | | | | |
| I+II | 18 | 10 | 55.56 | 7.204 | 0.007 |
| III+IV | 29 | 26 | 89.66 | | |
level was significantly elevated in primary stomach cancer patients, especially those patients with lymph node metastasis, distal recurrence, and lower-differentiation tumors [12]. The lung cancer also had higher Ki-67 antigen levels compared to normal ones [13].

Table 3. Ki-67 expression and clinical indexes.

| Clinical parameter          | N  | Positive cases | Percentage | χ² value | P value |
|----------------------------|----|----------------|------------|----------|---------|
| Age (yrs)                  |    |                |            |          |         |
| <60                        | 31 | 24             | 77.42      | 0.693    | 0.405   |
| ≥60                        | 16 | 14             | 87.50      |          |         |
| Sex                        |    |                |            |          |         |
| Male                       | 27 | 22             | 81.48      | 0.016    | 0.898   |
| Female                     | 20 | 16             | 80.00      |          |         |
| Disease history (yr)       |    |                |            |          |         |
| <3                         | 15 | 11             | 73.33      | 0.804    | 0.370   |
| ≥3                         | 32 | 27             | 84.38      |          |         |
| Tumor size (cm)            |    |                |            |          |         |
| <2                         | 19 | 14             | 73.68      | 1.058    | 0.304   |
| ≥2                         | 28 | 24             | 85.71      |          |         |
| Type                       |    |                |            |          |         |
| Squamous                   | 4  | 3              | 75.00      | 0.097    | 0.759   |
| Adenoma                    | 43 | 35             | 81.40      |          |         |
| Pathological type          |    |                |            |          |         |
| Low                        | 10 | 10             | 100.00     |          |         |
| Moderate                   | 21 | 18             | 85.71      | 4.875    | 0.027   |
| High                       | 16 | 10             | 62.50      |          |         |
| Lymph node metastasis      |    |                |            |          |         |
| Yes                        | 24 | 23             | 95.83      | 7.111    | 0.008   |
| No                         | 23 | 15             | 65.22      |          |         |
| TNM staging                |    |                |            |          |         |
| I+II                       | 18 | 11             | 61.11      | 7.342    | 0.007   |
| III+IV                     | 29 | 27             | 93.10      |          |         |

Table 4. COX regression survival analysis within 47 cases of hepatolithiasis with bile duct carcinoma.

| Parameter                | B value | Standard error | Wald χ² value | P value | RR value | 95%CI   |
|--------------------------|---------|----------------|---------------|---------|----------|---------|
| Age                      | 0.02    | 0.04           | 0.23          | 0.65    | 1.02     | 0.97–1.08|
| Sex                      | 0.37    | 0.31           | 1.40          | 0.25    | 0.81     | 0.80–2.62|
| Tumor size               | –       | –              | 0.07          | 0.98    | 1.00     | –       |
| Pathological type        | –0.04   | 0.14           | 0.02          | 0.93    | 0.74     | 0.55–1.76|
| Disease period           | –0.07   | 0.24           | 0.07          | 0.81    | 0.99     | 0.61–1.49|
| Lymph node metastasis    | 0.33    | 0.30           | 1.19          | 0.29    | 0.89     | 0.78–2.46|
| Ki-67 positive           | 0.75    | 0.24           | 10.68         | 0.00    | 1.54     | 1.35–3.27|
| COX-2 positive           | 1.14    | 0.26           | 20.23         | 0.00    | 1.59     | 1.39–3.07|
| High differentiation     | –       | –              | 14.92         | 0.00    | 1.88     | –       |
| Moderate differentiation  | 0.73    | 0.32           | 5.40          | 0.03    | 2.05     | 1.13–3.75|
| Low differentiation       | 0.87    | 0.30           | 8.54          | 0.01    | 2.37     | 1.34–4.26|
| TNM stage III and IV     | 1.08    | 0.21           | 17.47         | 0.00    | 2.68     | 1.76–4.81|

COX-2 belongs to the immediate early gene family and has trace amounts in placenta, kidney, and brain tissues. The expression of COX-2 is only elevated when cells receive inflammatory stimuli and growth factor-like molecules, with its start codon playing an important role in transcriptional modulation.
Recently, COX-2 has been suggested to be involved in the pathogenesis and progression of malignant tumors, as it has higher expression in most malignant tumor tissues [14], and may participate in the differentiation, proliferation, metastasis, neoangiogenesis, and anti-apoptosis, thereby lowering the cell-to-cell adhesion and facilitating disease progression [15]. Within the occurrence and progression of malignant tumors, angiogenesis plays an important role. High-level expression of COX-2 may inhibit the immune response and escape from immune surveillance, thus facilitating formation of tumor vessels. For example, COX-2 has been shown to be highly expressed in upper urinary epitheloma by cDNA microarray analysis [16,17]. Other studies also reported the correlation between COX-2 expression level and the invasion, metastasis, and prognosis of bladder papillary tumors [18].

In this study, we analyzed the expression pattern of COX-2 and Ki-67 in hepatolithiasis with bile duct carcinoma tissues and its clinical significance. Table 1 shows that only 1 out of 30 normal bile duct tissue had COX-2 expression, significantly lower than that in the hepatolithiasis (29.79%) or bile duct carcinoma group (76.60%). These results suggest the possible involvement of COX-2 in the pathogenesis of hepatolithiasis with bile duct carcinoma, consistent with results of clinical studies [19]. Other studies that the inflammation of gland and bile duct epithelial and secondary hyperplasia are indicators of bile duct cancer [20], which is preceded by hepatolithiasis, cholangitis, and bile duct epithelial hyperplasia. In this study, we also discovered higher expression level of COX-2 in hepatolithiasis compared to normal bile duct, suggesting that the abnormal COX-2 expression may be an early indicator of bile duct cancer. Further correlation analysis found elevated COX-2 expression in bile duct cancer patients with advanced TNM stage, higher malignancy, and lymph node metastasis (Table 2). Therefore, COX-2 expression may be closely related to the occurrence and metastasis of bile duct cancer. The assay of COX-2 expression in patients who are susceptible to hepatolithiasis with bile duct cancer may help to make early diagnosis.

No Ki-67 protein has been found in normal bile duct tissues (Table 1, Figure 1), suggesting its lower expression under normal circumstances. However, hepatolithiasis and bile duct cancer tissues had 25.35% and 80.85% Ki-67 expression, respectively, significantly higher than in normal tissues. Our results are consistent with previous reports [21,22], suggesting the elevated Ki-67 expression in hepatolithiasis and bile duct carcinoma. Correlation analysis showed a strong relationship between Ki-67 and TNM stage, lymph node metastasis, and differentiation degree (Table 3). Further analysis showed that bile duct cancer with positive Ki-67 or COX-2 expression had 1.54- and 1.59-fold mortality rates, respectively, compared to those with negative expression. Those 2 proteins, although they had minimal expression in normal cells, can be activated by tumor-related pathways such as growth factor, oncogene, and cytokines. Ki-67 and COX-2 are closely related with short-term prognosis of bile duct patients complicated with hepatolithiasis.

Conclusions

Our results collectively showed that COX-2 and Ki-67 were highly expressed in hepatolithiasis with bile duct carcinoma tissues, and might promote the pathogenesis, progression, and metastasis of bile duct tumors. These 2 factors are correlated with patient prognosis and should receive further research attention.

References:

1. Ndengele MM, Cuzzocrea S, Esposito E et al: Cyclooxygenases 1 and 2 contribute to peroxynitrite-mediated inflammatory pain hypersensitivity. Faseb J, 2008; 22(9): 3154–64
2. Kametaka H, Makino H, Fukada T et al: A case of synchronous triple cancer treated with multidisciplinary therapy – cancers in the middle part of the extrahepatic bile duct, the pancreas head, and the supraglottis. Gan To Kagaku Ryoho, 2014; 41(12): 2459–61 [in Japanese]
3. Hatzaras I, Schmidt C, Muscarella P et al: Elevated CA 19-9 portends poor prognosis in patients undergoing resection of biliary malignancies. HPB (Oxford), 2010; 12(2): 134–38
4. Sarafoleau D, Postelnicu V, Josif C et al: The role of p53, PCNA and Ki-67 as outcome predictors in the treatment of laryngeal cancer. J Med Life, 2009; (2(2)): 219–26
5. Cheong MC, Chia SK, Voduc D et al: Ki67 expression, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst, 2009; 101(10): 736–50
6. Liu Y, Zhang JB, Qin Y et al: PROX1 promotes hepatocellular carcinoma metastasis by way of up-regulating hypoxia-inducible factor 1alpha expression and protein stability. Hepatology, 2013; 58(2): 692–705
7. Cimpean AM, Mazuru V, Sapefrati L et al: Prox 1, VEGF-C and VEGFR3 expression during cervical neoplasia progression as evidence of an early lymphangiogenic switch. Histol Histopathol, 2012; 27(12): 1543–50
8. Okazaki T, Ajiki T, Shinozaki K et al: Long-term survivor of unresectable bile duct cancer complicated with sclerosing cholangitis treated with chemotherapy. Gan To Kagaku Ryoho, 2014; 41(12): 1542–44 [in Japanese]
9. Sood R, Minzel W, Rimon G et al: Down-regulation of cyclooxygenase-2 by the carboxyl tail of the angiotensin II type 1 receptor. J Biol Chem, 2014; 289(45): 31473–79
10. Choi SB, Han HJ, Park PJ et al: Disease recurrence patterns and analysis of clinicopathological prognostic factors for recurrence after resection for distal bile duct cancer. Am Surg, 2015; 81(3): 289–96
11. Hsu CK, Lee IT, Lin CC et al: Sphingosine-1-phosphate mediates COX-2 expression and PGE2 /IL-6 secretion via c-Src-dependent AP-1 activation. J Cell Physiol, 2015; 230(3): 702–15
12. Hosoda Y, Tomimaru Y, Wada H et al: A case of resected liver metastasis from rectal cancer with bile duct stricture after radiofrequency ablation. Gan To Kagaku Ryoho, 2014; 41(12): 2116–18 [in Japanese]
13. Koohdani F, Sasani F, Mohammad K, Mehdiipour P et al: Comparison of Ki-67 antigen expression and K-ras mutation in lung tumours induced by urethane in mice. Singapore Med J, 2009; 50(7): 729–33
14. Ruan D, So SP: Prostaglandin E2 produced by inducible COX-2 and mPGES-1 promoting cancer cell proliferation in vitro and in vivo. Life Sci, 2014; 116(1): 43–50
15. Fatema CN, Zhao S, Zhao Y et al: Monitoring tumor proliferative response to radiotherapy using (18)F-fluorothymidine in human head and neck cancer xenograft in comparison with Ki-67. Ann Nucl Med, 2013; 27(4): 355–62
16. Jeon HG, Jeong IG, Bae J et al: Expression of Ki-67 and COX-2 in patients with upper urinary tract urothelial carcinoma. Urology, 2010; 76(2): 513. e7–12
17. Lyons TR, Borges VF, Betts CB et al: Cyclooxygenase-2-dependent lymphangiogenesis promotes nodal metastasis of postpartum breast cancer. J Clin Invest, 2014; 124(9): 3901–12
18. Ogata DC, Marcondes CA, Tuon FF et al: Superficial papillary urothelial neoplasms of the bladder (PTA E PT1): correlation of expression of P53, Ki-67 and CK20 with histologic grade, recurrence and tumor progression. Rev Col Bras Cir, 2012; 39(5): 394–400
19. Altavilla G, Staffieri A, Busatto G et al: Expression of p53, p16INK4A, pRB, p21WAF1/CIP1, p27KIP1, cyclin D1, Ki-67 and HPV DNA in sinonasal endophytic Schneiderian (inverted) papilloma. Acta Otolaryngol, 2009; 129(11): 1242–49
20. Chang SL, Hu S, Hung SI, et al: A comparison of Ki-67 antigen presentation in acute generalized exanthematous pustulosis and pustular psoriasis. Arch Dermatol Res, 2010; 302(7): 525–29
21. Zhou YM, Yin ZF, Yang JM et al: Risk factors for intrahepatic cholangiocarcinoma: a case-control study in China. World J Gastroenterol, 2008; 14(4): 632–35
22. Iso Y, Kita J, Kato M et al: When hepatic-side ductal margin is positive in N cases, additional resection of the bile duct is not necessary to render the negative hepatic-side ductal margin during surgery for extrahepatic distal bile duct carcinoma. Med Sci Monit, 2014; 20: 471–75

Indexed in: [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System] [ISI Journals Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica] [Chemical Abstracts/CAS] [Index Copernicus]

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License